(MENAFN- ProactiveInvestors)Cancer test developer VolitionRx (NYSE:VNRX) has been granted its first US patent. VolitionRx's tests are based on the science of Nucleosomics which identifies and measures nucleosomes in the bloodstream and that are an indication that cancer is present. Already protected in Europe the patent covers a test that using a single drop of blood can detect epigenetic changes that affect chromosome structure in cancer. Dr Jake Micallef chief scientific officer said: "VolitionRx is building a world-wide portfolio of intellectual property to protect its Nucleosomics technology 'The grant of US Patent 9128086 provides protection to key technology that underpins our NuQtests as we continue towards our goals of commercialization." Cameron Reynolds chief executive added: 'The grant of this broad-reaching wholly-owned and royalty-free patent is a critical step in protecting VolitionRx's intellectual property." The company revealed yesterday that its NuQ colorectal cancer blood test achieved a high success rate in a trial held in Denmark. Interim results from a 4800-subject trial at Hvidovre Hospital indicated NuQ blood tests detected 81% of colorectal cancers at 78% specificity equally well for both for early- and late-stage cancers.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.